论文部分内容阅读
吉非替尼是一种口服选择性表皮生长因子受体酪氨酸激酶抑制剂,用于治疗非小细胞肺癌。吉非替尼可引起间质性肺疾病(ILD),引起ILD的平均时间为24～42d,发生率为0.44%～2.0%,病死率为0.12%～0.5%。ILD主要临床表现为呼吸困难、胸闷、干咳和发绀等,胸部影像学检查可见双肺弥漫性浸润性阴影及蜂窝状间质阴影。高龄、男性、吸烟史、ILD史和长时间用药等为吉非替尼致ILD的危险因素。用药期间应进行胸部影像学检查,一旦发现ILD应及时停药,并给予静脉注射大剂量糖皮质激素、吸氧、抗感染等对症支持治疗,一般预后良好。
Gefitinib is an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor used to treat non-small cell lung cancer. Gefitinib can cause interstitial lung disease (ILD), causing the average time ILD 24 ~ 42d, the incidence was 0.44% to 2.0%, the mortality rate was 0.12% to 0.5%. ILD main clinical manifestations of dyspnea, chest tightness, dry cough and cyanosis, chest radiography showed diffuse infiltration of lung shadow and cellular interstitial shadow. Elderly, men, smoking history, ILD history and long-term medication for the gefitinib cause ILD risk factors. Chest imaging examination should be carried out during the medication, if ILD should be promptly discontinued, and given intravenous high-dose glucocorticoid, oxygen, anti-infection symptomatic and supportive treatment, the general prognosis is good.